Clinical trials: Positron-Emission Tomography
- Condition Positron-Emission Tomography
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Neuroblastoma
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
- Trial name
- NCT04724369
- Testing
- 18F-MFBG
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Normal Human Subjects
Single Photon Emission Computed Tomography of the Normal Human Brain
The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states.
- Trial name
- NCT01203891
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Amen Clinics, Inc.
Alzheimer's Disease
Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians
This study is designed to validate the Japanese electronic florbetapir (18F) interpretation training program intended for post-approval implementation in Japan.
- Trial name
- NCT02029547
- Testing
- Florbetapir (18F)
- Where
- Japan
- Sponsor
- Avid Radiopharmaceuticals
Neuroblastoma
A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
This is a prospective image revaluation study designed to assess the performance of 18F-mFBG PET imaging in detecting the presence of neuroblastoma.
- Trial name
- 101-305 (NCT07833631)
- Testing
- 18F-MFBG
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Neuroblastoma, Pheochromocytoma
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter.
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT06233903
- Testing
- 18F-mFBG
- Where
- United States
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Alzheimer Disease
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
- Trial name
- NCT03901092
- Testing
- flortaucipir F 18
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Avid Radiopharmaceuticals
Retrospective Study, Glioma
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
This study is designed to prospectively analyze [18F]FET PET image data obtained retrospectively in the routine clinical care of glioma patients.
- Conditions
- Retrospective Study, Glioma, Brain Neoplasms
- Trial name
- NCT07238322
- Testing
- 18F(FET)PET
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 253 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Cognitive Decline
Flortaucipir 18F PET Imaging in BIOCARD Study
This study is designed to assess the imaging characteristics of Flortaucipir (18F-AV-1451) in subjects who participated in the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study at Johns Hopkins University.
- Trial name
- NCT03052972
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Sarcoma, Melanoma
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "[F-18] RGDK5," to evaluate biodistribution and…
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer
- Trial name
- K5 (NCT00743353)
- Testing
- F-18 RGD-K5
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
Chronic Traumatic Encephalopathy
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
- Trial name
- NCT02079766
- Testing
- florbetapir F 18, Flortaucipir F18
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of diagnosis, staging and monitoring response to…
- Conditions
- Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage, Primary Myelofibrosis, Prefibrotic Stage, Polycythemia Vera
- Trial name
- NCT03121599
- Testing
- Diagnostic (18F-FLT PET/CT)
- Where
- Qatar
- Volunteers
- 3 people
- Sponsor
- Hamad Medical Corporation
Healthy Volunteers
A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants
The purpose of this study is to measure the regional distribution and binding of [11C]AZ14132516 to CCR9 in the abdomen using PET-CT examination in healthy participants.
- Trial name
- NCT05818514
- Testing
- [11C]AZ14132516
- Where
- Sweden
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Head and Neck Cancer
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after [F-18] HX4 injection.
- Trial name
- NCT01506427
- Testing
- [F-18] HX4
- Where
- United States
- Sponsor
- Siemens Molecular Imaging
Primary Sjögren's Syndrome
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method…
- Trial name
- NCT02495129
- Testing
- VAY736 lower dose, VAY736 higher dose
- Sponsor
- Novartis Pharmaceuticals